stockportfolio.pro
Stocks / DGX vs UTHR
DGX vs UTHR
Quest Diagnostics Incorporated and United Therapeutics Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Quest Diagnostics Incorporated (DGX) | United Therapeutics Corporation (UTHR) | |
|---|---|---|
| Market cap | $22.6B | $23.0B |
| Revenue (latest FY) | $11.04B | $3.18B |
| Net income (latest FY) | $992.00M | $1.33B |
| Revenue growth (5y CAGR) | 3.2% | 16.5% |
| Net margin | 9.0% | 41.9% |
| Return on equity | 13.8% | 18.8% |
| P/E ratio | 22.6 | 20.0 |
| Dividend yield | 1.7% | — |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DGX — free Open UTHR — freeFrequently asked questions
Which is bigger, DGX or UTHR?
United Therapeutics Corporation is larger by market capitalization — $23.0B versus $22.6B.
Which grows faster, DGX or UTHR?
Over the last five fiscal years, United Therapeutics Corporation grew revenue faster — 16.5%/yr versus 3.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.